Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

LeMaitre Vascular Sees Q4 EPS $0.34-$0.38 Vs $0.34 Est.; Revenue $48M-50M Vs $50.19M Est.; FY23 EPS $1.32-$1.36 Vs $1.28 Est. Revenue $192.6M-$194.6M Vs $195.01M Est.

Author: Benzinga Newsdesk | November 01, 2023 05:43pm

Business Outlook

Q4 2023 GuidanceFull Year 2023 Guidance 
Sales$48.0mm - $50.0mm

(Mid: $49.0mm, +20%, +16% Org.)
$192.6mm - $194.6mm

(Mid: $193.6mm, +20%, +17% Org.)
Gross Margin65.0%64.9%
Op. Inc.$9.4mm - $10.7mm

(Mid: $10.0mm, +44%)
$35.9mm - $37.2mm

(Mid $36.5mm, +36%)
Op. Inc. Ex-Special*-$36.4mm - $37.7mm

(Mid $37.0mm, +24%)
EPS$0.34 - $0.38

(Mid: $0.36, +43%)
$1.30 - $1.35

(Mid: $1.33, +42%)
EPS Ex-Special*-$1.32 - $1.36

(Mid: $1.34, +26%)

*Special charges are related to the St. Etienne factory closure.

Posted In: LMAT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist